On May 26, Abivax S.A. rose 5.03% in regular trading, trading at $127.99/share, with trading volume of $85.10 million.

On the news front, the company disclosed that as of March 31, it held cash, cash equivalents, and short-term investments totaling €491.6 million. Based on current operating assumptions, the company projects its cash runway extending into Q4 of next year. This ample liquidity position effectively alleviated market concerns over the sustainability of its core drug development programs.

Market sentiment was further bolstered by institutional bullish views. The majority of sell-side analysts maintained buy ratings on the stock with target prices above the current trading level. Investors are closely watching the company's financing and royalty arrangements and their positive implications for its long-term cash flow trajectory. Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate immune responses in chronic inflammatory diseases, with its lead candidate obefazimod in Phase 3 trials for ulcerative colitis and in development for Crohn's disease.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)